JP2025179137A5 - - Google Patents
Info
- Publication number
- JP2025179137A5 JP2025179137A5 JP2025145171A JP2025145171A JP2025179137A5 JP 2025179137 A5 JP2025179137 A5 JP 2025179137A5 JP 2025145171 A JP2025145171 A JP 2025145171A JP 2025145171 A JP2025145171 A JP 2025145171A JP 2025179137 A5 JP2025179137 A5 JP 2025179137A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- pain
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063037001P | 2020-06-10 | 2020-06-10 | |
| US63/037,001 | 2020-06-10 | ||
| JP2021090960A JP7739051B2 (ja) | 2020-06-10 | 2021-05-31 | シクロブチルジヒドロキノリンスルホンアミド化合物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021090960A Division JP7739051B2 (ja) | 2020-06-10 | 2021-05-31 | シクロブチルジヒドロキノリンスルホンアミド化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025179137A JP2025179137A (ja) | 2025-12-09 |
| JP2025179137A5 true JP2025179137A5 (https=) | 2026-02-27 |
Family
ID=76797115
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021090960A Active JP7739051B2 (ja) | 2020-06-10 | 2021-05-31 | シクロブチルジヒドロキノリンスルホンアミド化合物 |
| JP2025145171A Pending JP2025179137A (ja) | 2020-06-10 | 2025-09-02 | シクロブチルジヒドロキノリンスルホンアミド化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021090960A Active JP7739051B2 (ja) | 2020-06-10 | 2021-05-31 | シクロブチルジヒドロキノリンスルホンアミド化合物 |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US12240839B2 (https=) |
| EP (2) | EP4165024B1 (https=) |
| JP (2) | JP7739051B2 (https=) |
| KR (1) | KR20230022996A (https=) |
| CN (2) | CN119735588A (https=) |
| AR (1) | AR122592A1 (https=) |
| AU (1) | AU2021288696A1 (https=) |
| BR (1) | BR112022025201A2 (https=) |
| CA (1) | CA3183889A1 (https=) |
| CL (1) | CL2022003499A1 (https=) |
| CO (1) | CO2022017903A2 (https=) |
| CR (1) | CR20220631A (https=) |
| DK (1) | DK4165024T3 (https=) |
| ES (1) | ES3037072T3 (https=) |
| FI (1) | FI4165024T3 (https=) |
| HR (1) | HRP20251229T1 (https=) |
| HU (1) | HUE072945T2 (https=) |
| IL (2) | IL326793A (https=) |
| JO (1) | JOP20220334A1 (https=) |
| LT (1) | LT4165024T (https=) |
| MA (1) | MA59968B1 (https=) |
| MX (2) | MX2022015856A (https=) |
| PE (1) | PE20230860A1 (https=) |
| PL (1) | PL4165024T3 (https=) |
| PT (1) | PT4165024T (https=) |
| RS (1) | RS67268B1 (https=) |
| SI (1) | SI4165024T1 (https=) |
| SM (1) | SMT202500328T1 (https=) |
| TW (1) | TWI899251B (https=) |
| UY (1) | UY39263A (https=) |
| WO (1) | WO2021252820A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7739051B2 (ja) | 2020-06-10 | 2025-09-16 | アムジエン・インコーポレーテツド | シクロブチルジヒドロキノリンスルホンアミド化合物 |
| JP2021195367A (ja) * | 2020-06-10 | 2021-12-27 | アムジエン・インコーポレーテツド | シクロプロピルジヒドロキノリンスルホンアミド化合物 |
| HRP20260068T1 (hr) | 2021-06-04 | 2026-02-27 | Vertex Pharmaceuticals Incorporated | Čvrsti farmaceutski oblici i režimi doziranja koji obuhvaćaju (2r,3s,4s,5r)-4-[[3-(3,4-difluor-2-metoksifenil)-4,5-dimetil-5-(trifluormetil)tetrahidrofuran-2-karbonil]amino]piridin-2-karboksamid |
| AU2022283934A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| CA3221938A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
| SMT202500481T1 (it) | 2021-06-04 | 2026-01-12 | Vertex Pharma | N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio |
| US20240400544A1 (en) | 2021-06-04 | 2024-12-05 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
| WO2022256842A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
| KR20240046891A (ko) * | 2021-08-12 | 2024-04-11 | 티와이케이 메디슨즈, 인코포레이티드 | 다환 화합물 및 그의 용도 |
| CA3257285A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | HETEROARYL COMPOUNDS FOR PAIN RELIEF |
| US20230382910A1 (en) | 2022-04-22 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2023205463A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| CA3256248A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | HETEROARYL COMPOUNDS FOR PAIN RELIEF |
| WO2024123815A1 (en) | 2022-12-06 | 2024-06-13 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
| WO2025090511A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing modulators of sodium channels and solid forms of the same for treating pain |
| WO2025090516A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing compounds for treating pain and solid forms thereof |
| WO2025090480A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2025090465A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| US20250186419A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens for treating pain |
| US20260001877A1 (en) | 2024-06-28 | 2026-01-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2026013449A2 (en) | 2024-07-11 | 2026-01-15 | Sea4Us - Biotecnologia E Recursos Marinhos, Sa | Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain |
| WO2026030525A1 (en) | 2024-07-31 | 2026-02-05 | Vertex Pharmaceuticals Incorporated | Zilvetrigine dosage forms and dosing regimens for treating pain |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| US4412994A (en) | 1980-04-24 | 1983-11-01 | Interx Research Corporation | Mannich-base hydroxamic acid prodrugs, compositions and use |
| US5707985A (en) | 1995-06-07 | 1998-01-13 | Tanabe Seiyaku Co. Ltd. | Naphthyl-, quinolyl- and isoquinolyl- sulfonamide derivatives as cell adhesion modulators |
| PA8444901A1 (es) | 1997-01-28 | 2000-05-24 | Hoffmann La Roche | Derivados de 5-aroilnaftaleno como agentes anti-inflamatorios |
| CN1315836C (zh) | 2002-04-26 | 2007-05-16 | 奥索-麦克尼尔药品公司 | 用作雄激素受体调节剂的2－(喹诺酮基)－稠合杂环 |
| BRPI0406778A (pt) | 2003-01-17 | 2006-01-17 | Warner Lambert Co | Antagonistas de receptores de androgênio |
| US7009052B2 (en) | 2003-03-20 | 2006-03-07 | Warner Lambert Company Llc | Sulfonamide derivatives |
| WO2006117762A2 (en) | 2005-05-03 | 2006-11-09 | Ranbaxy Laboratories Limited | Antimicrobial agents |
| MX2007014180A (es) | 2005-05-10 | 2008-01-14 | Vertex Pharma | Derivados biciclicos como moduladores de canales de iones. |
| CA2608599A1 (en) | 2005-05-16 | 2006-11-23 | Vertex Pharmaceuticals Incorporated | Bicyclic derivatives as modulators of ion channels |
| GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| TWI385161B (zh) | 2006-02-02 | 2013-02-11 | Mitsubishi Tanabe Pharma Corp | 含氮雜雙環化合物 |
| CA2741024A1 (en) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| GB0907551D0 (en) * | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| CN102471235A (zh) | 2009-07-11 | 2012-05-23 | 拜耳医药股份有限公司 | 利用环烷基的放射性标记方法 |
| CN102030780B (zh) * | 2010-10-26 | 2014-01-29 | 浙江大学 | 一种手性螺环磷酸和制备方法及其应用 |
| MX2014001851A (es) | 2011-08-17 | 2014-10-24 | Amgen Inc | Inhibidores del canal de heteroarilo sodio. |
| US9012443B2 (en) | 2011-12-07 | 2015-04-21 | Amgen Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
| WO2013122897A1 (en) | 2012-02-13 | 2013-08-22 | Amgen Inc. | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors |
| WO2013134518A1 (en) | 2012-03-09 | 2013-09-12 | Amgen Inc. | Sulfamide sodium channel inhibitors |
| US9776995B2 (en) | 2013-06-12 | 2017-10-03 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
| WO2016124139A1 (zh) | 2015-02-04 | 2016-08-11 | 上海海雁医药科技有限公司 | 杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途 |
| EA032928B1 (ru) | 2015-03-02 | 2019-08-30 | Эмджен Инк. | Бициклические кетосульфонамидные соединения |
| JP6903663B2 (ja) | 2015-12-18 | 2021-07-14 | アムジエン・インコーポレーテツド | アルキルジヒドロキノリンスルホンアミド化合物 |
| MX378012B (es) * | 2015-12-18 | 2025-03-10 | Amgen Inc | Compuestos de alquinil dihidroquinolina sulfonamida. |
| CN109563045B (zh) * | 2016-03-21 | 2022-08-23 | 斯克里普斯研究学院 | Pd(II)-催化的对映选择性β-亚甲基C(sp3)-H键活化 |
| JP7739051B2 (ja) | 2020-06-10 | 2025-09-16 | アムジエン・インコーポレーテツド | シクロブチルジヒドロキノリンスルホンアミド化合物 |
| JP2021195367A (ja) | 2020-06-10 | 2021-12-27 | アムジエン・インコーポレーテツド | シクロプロピルジヒドロキノリンスルホンアミド化合物 |
| KR20240046891A (ko) | 2021-08-12 | 2024-04-11 | 티와이케이 메디슨즈, 인코포레이티드 | 다환 화합물 및 그의 용도 |
| MX2024002176A (es) | 2021-08-19 | 2024-03-12 | Amgen Inc | Preparacion estereoselectiva de ciclobutano trans halo. |
-
2021
- 2021-05-31 JP JP2021090960A patent/JP7739051B2/ja active Active
- 2021-06-10 EP EP21737878.5A patent/EP4165024B1/en active Active
- 2021-06-10 CR CR20220631A patent/CR20220631A/es unknown
- 2021-06-10 RS RS20250992A patent/RS67268B1/sr unknown
- 2021-06-10 BR BR112022025201A patent/BR112022025201A2/pt unknown
- 2021-06-10 WO PCT/US2021/036896 patent/WO2021252820A1/en not_active Ceased
- 2021-06-10 MX MX2022015856A patent/MX2022015856A/es unknown
- 2021-06-10 SM SM20250328T patent/SMT202500328T1/it unknown
- 2021-06-10 US US17/633,151 patent/US12240839B2/en active Active
- 2021-06-10 AR ARP210101586A patent/AR122592A1/es unknown
- 2021-06-10 TW TW110121155A patent/TWI899251B/zh active
- 2021-06-10 SI SI202130354T patent/SI4165024T1/sl unknown
- 2021-06-10 CN CN202510007130.6A patent/CN119735588A/zh active Pending
- 2021-06-10 FI FIEP21737878.5T patent/FI4165024T3/fi active
- 2021-06-10 CA CA3183889A patent/CA3183889A1/en active Pending
- 2021-06-10 EP EP25188659.4A patent/EP4653050A3/en active Pending
- 2021-06-10 PT PT217378785T patent/PT4165024T/pt unknown
- 2021-06-10 PE PE2022002892A patent/PE20230860A1/es unknown
- 2021-06-10 UY UY0001039263A patent/UY39263A/es unknown
- 2021-06-10 CN CN202180040963.2A patent/CN115697971B/zh active Active
- 2021-06-10 IL IL326793A patent/IL326793A/en unknown
- 2021-06-10 KR KR1020237000972A patent/KR20230022996A/ko active Pending
- 2021-06-10 DK DK21737878.5T patent/DK4165024T3/da active
- 2021-06-10 ES ES21737878T patent/ES3037072T3/es active Active
- 2021-06-10 LT LTEPPCT/US2021/036896T patent/LT4165024T/lt unknown
- 2021-06-10 IL IL298325A patent/IL298325B1/en unknown
- 2021-06-10 MA MA59968A patent/MA59968B1/fr unknown
- 2021-06-10 HU HUE21737878A patent/HUE072945T2/hu unknown
- 2021-06-10 JO JOP/2022/0334A patent/JOP20220334A1/ar unknown
- 2021-06-10 HR HRP20251229TT patent/HRP20251229T1/hr unknown
- 2021-06-10 PL PL21737878.5T patent/PL4165024T3/pl unknown
- 2021-06-10 AU AU2021288696A patent/AU2021288696A1/en active Pending
- 2021-06-11 US US17/344,947 patent/US20210387978A1/en not_active Abandoned
-
2022
- 2022-12-09 MX MX2025010506A patent/MX2025010506A/es unknown
- 2022-12-09 CO CONC2022/0017903A patent/CO2022017903A2/es unknown
- 2022-12-09 CL CL2022003499A patent/CL2022003499A1/es unknown
-
2025
- 2025-01-28 US US19/039,379 patent/US20250171425A1/en active Pending
- 2025-09-02 JP JP2025145171A patent/JP2025179137A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025179137A5 (https=) | ||
| JP2021504443A5 (https=) | ||
| JP2023524597A5 (https=) | ||
| JP2023524018A5 (https=) | ||
| JP2024050527A5 (https=) | ||
| AR089134A1 (es) | Arilos y heteroarilos biciclicos inhibidores de los canales de sodio | |
| CN1436082A (zh) | 用于治疗肝炎病毒感染的3′－或2′－羟甲基取代的核苷衍生物 | |
| HRP20251229T1 (hr) | Spojevi ciklobutil dihidrohinolin sulfonamida | |
| WO2001025181A1 (en) | Carboxylic acid derivatives and drugs containing the same | |
| JP2012505891A5 (https=) | ||
| JP2011513367A5 (https=) | ||
| JP2018531982A5 (https=) | ||
| JP2004535466A5 (https=) | ||
| RU2002127682A (ru) | Замещенные бета-карболины | |
| JP2014523901A5 (https=) | ||
| FR2545485A1 (fr) | Nouveaux derives d'amine, leurs sels, procede pour les preparer, et agent anti-ulcereux les contenant | |
| JP2015522036A5 (https=) | ||
| JP2008505874A5 (https=) | ||
| RU2008143457A (ru) | Производные-2-пиразинона для лечения заболевания или состояния, при которых полезно ингибирование активности нейтрофильной эластазы | |
| CN101432275A (zh) | 11-β-羟类固醇脱氢敏1的抑制剂 | |
| JP2023520924A5 (https=) | ||
| JP2007523142A5 (https=) | ||
| CN103635466A (zh) | 芳族酰胺及其用途 | |
| RU2018107839A (ru) | Замещенные производные гуанидина | |
| JP2020111571A5 (https=) |